Potential Link Between Regular Opioid Use and Increased Dementia Risk
New research associates regular opioid consumption with a higher risk of dementia and brain volume reduction, emphasizing cautious opioid prescribing for chronic pain management.
Recent research published in Alzheimer's & Dementia reveals a significant association between consistent opioid use and a heightened risk of developing dementia, especially vascular dementia. Led by Dr. Sha Feng from the Shenzhen Institute of Advanced Technology and collaborating with experts from Massachusetts Veterans Home and the University of Pennsylvania, the study highlights critical insights into how opioids may influence cognitive health.
Chronic non-cancer pain (CNCP), a condition persisting for over three months unrelated to cancer, saw widespread opioid prescriptions starting in the mid-1990s. This increase has raised concerns over dependence, misuse, and potential neurological impacts. Existing evidence suggests that opioids can alter the brain's endogenous opioid system and impair regions such as the hippocampus, which are vital for cognitive function.
The study analyzed data from 197,673 UK Biobank participants aged between 37 and 73 years over an average follow-up period of nearly 14 years. Employing advanced statistical models to control for confounding factors, researchers found that individuals who regularly used opioids faced a 20% higher overall risk of developing dementia compared to non-opioid analgesic users. Those on high-potency opioids faced an even greater risk, exceeding 70%. Conversely, individuals taking non-opioid painkillers showed dementia risk comparable to those not using opioids.
Neuroimaging assessments further revealed that regular, strong opioid use was associated with reductions in total brain volume, white matter, and hippocampal size—regions crucial for memory and cognition. Additionally, regular opioid use was linked to decreased fluid intelligence, although no significant decline was observed in prospective memory.
These findings underscore the importance of evaluating opioid potency and cumulative exposure when considering risks related to cognitive decline. The research underscores the necessity for cautious opioid prescribing, especially for long-term pain management, to mitigate potential adverse effects on brain health.
Source: https://medicalxpress.com/news/2025-07-regular-opioid-dementia.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
AI Innovation Enables Detection of Fatty Liver Disease via Chest X-Rays
Innovative AI model analyzes routine chest X-rays to detect fatty liver disease, offering a cost-effective and accessible diagnostic method that could transform early screening strategies.
Customized Antibiotic Dosing: Why Obesity Alters Drug Effectiveness
Emerging research reveals that obesity alters how antibiotics are processed in the body, highlighting the need for personalized dosing guidelines to improve infection treatment outcomes in obese patients.
Canada's New Guidelines for Neurotechnology Regulation Emphasize Indigenous Rights and Ethical Innovation
Canada is developing new regulatory guidelines for neurotechnology, emphasizing ethical innovation, Indigenous rights, and public trust to guide responsible neurotech advancement.
Why the ALS Drug BIIB078 Failed Despite Target Engagement
A groundbreaking study explains why the promising ALS drug BIIB078 failed despite reaching its target in the CNS. The research highlights the challenges in drug delivery and the need for better biomarkers to measure treatment effectiveness in ALS. Source: Emory University.